"Best Buy" NSAID Rxs Up Since Vioxx Withdrawal, But Mobic Growing Faster, Consumers Union Says
This article was originally published in The Pink Sheet Daily
Prescriptions for Abbott/Boehringer Ingelheim's Mobic doubled from September to March and the average retail price rose 9% in the same period, Consumers Union notes. Scripts for ibuprofen were up 28%, but prices were "relatively flat," the report says.
You may also be interested in...
Boehringer Ingelheim brand rings up $293 mil. in first quarter sales as biggest beneficiary from COX-2 safety issues. Mobic loses exclusivity April 13, although generics are unlikely to enter the market for at least nine months.
Sales of the non-steroidal anti-inflammatory agent jumped 177% in the fourth quarter on the heels of Merck's withdrawal of Vioxx. Abbott expects sales of Mobic to reach $1 bil. in 2005. The levothyroxine brand Synthroid is retaining 70% of the share it held before entry of generic competition.
Pfizer’s statin is rated the best value for patients needing to reduce LDL cholesterol more than 40%, but generic lovastatin is best for patients needing a smaller reduction. Consumer Reports publisher posts drug comparison reports for statins, NSAIDs and PPIs on its website.